Goldman Sachs
NUVB icon

Goldman Sachs’s Nuvation Bio NUVB Stock Holding History

Goldman Sachs’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Sell
1,904,686
-25,267
-1% -$123K ﹤0.01% 3167
2026
Q1 		$8.28M Buy
1,929,953
+233,940
+14% +$1.3M ﹤0.01% 3221
2025
Q4 		$15.2M Buy
1,696,013
+493,397
+41% +$3.06M ﹤0.01% 2651
2025
Q3 		$4.45M Sell
1,202,616
-275,428
-19% -$751K ﹤0.01% 3752
2025
Q2 		$2.88M Buy
1,478,044
+453,421
+44% +$944K ﹤0.01% 3893
2025
Q1 		$1.8M Sell
1,024,623
-1,005,151
-50% -$2.29M ﹤0.01% 4239
2024
Q4 		$5.4M Buy
2,029,774
+705,604
+53% +$1.82M ﹤0.01% 3377
2024
Q3 		$3.03M Buy
1,324,170
+184,664
+16% +$563K ﹤0.01% 3775
2024
Q2 		$3.33M Sell
1,139,506
-320
-0% -$976 ﹤0.01% 3527
2024
Q1 		$4.15M Buy
1,139,826
+345,718
+44% +$664K ﹤0.01% 3275
2023
Q4 		$1.2M Buy
794,108
+381,555
+92% +$491K ﹤0.01% 4277
2023
Q3 		$553K Sell
412,553
-88,944
-18% -$148K ﹤0.01% 4613
2023
Q2 		$903K Buy
501,497
+103,356
+26% +$176K ﹤0.01% 4411
2023
Q1 		$661K Buy
398,141
+156,991
+65% +$318K ﹤0.01% 4667
2022
Q4 		$463K Sell
241,150
-303,197
-56% -$613K ﹤0.01% 4908
2022
Q3 		$1.22M Buy
544,347
+399,301
+275% +$1.14M ﹤0.01% 4374
2022
Q2 		$470K Sell
145,046
-571,399
-80% -$2.49M ﹤0.01% 5121
2022
Q1 		$3.77M Buy
716,445
+569,597
+388% +$3.2M ﹤0.01% 3622
2021
Q4 		$1.25M Buy
146,848
+92,075
+168% +$846K ﹤0.01% 4650
2021
Q3 		$545K Sell
54,773
-106,556
-66% -$966K ﹤0.01% 5142
2021
Q2 		$1.5M Sell
161,329
-58,964
-27% -$672K ﹤0.01% 4451
2021
Q1 		$2.3M Buy
220,293
+210,293
+2,103% +$2.35M ﹤0.01% 3858
2020
Q4 		$117K Buy
+10,000
New +$104K ﹤0.01% 5266

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs's NUVB Position: Q2 2026 in Review

Goldman Sachs reduced its Nuvation Bio (NUVB) stake by 1.3% in Q2 2026, selling an estimated $123K and leaving 1,904,686 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3167.

Goldman Sachs first reported a position in NUVB in Q4 2020 and has held it in 23 quarters since. The position peaked at $15.2M in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Goldman Sachs held 1,904,686 shares of Nuvation Bio worth $10.8M as of Q2 2026.
  • Goldman Sachs sold 25,267 Nuvation Bio shares in Q2 2026, an estimated $123K.
  • Nuvation Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3167 holding.
  • Goldman Sachs first reported a position in Nuvation Bio in Q4 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Nuvation Bio position peaked at $15.2M in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.